fog-001
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 19, 2023 (NCT05919264)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adamantinoma · Phase 1/Phase 2
- Adenomatous Polyposis Coli · Phase 1/Phase 2
- beta Catenin · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Desmoid Tumors · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Wnt Signaling Pathway · Phase 1/Phase 2
Mechanism of action
- Catenin beta-1INHIBITOR
CTNNB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05919264 | Phase 1/Phase 2 (Phase 2) | May 19, 2023 | Fog Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fog Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1